These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 8796866)
21. Antisense oligonucleotides: a new therapeutic approach. Temsamani J; Guinot P Biotechnol Appl Biochem; 1997 Oct; 26(2):65-71. PubMed ID: 9357101 [TBL] [Abstract][Full Text] [Related]
22. Cellular and Antibody Based Approaches for Pediatric Cancer Immunotherapy. Huang MA; Krishnadas DK; Lucas KG J Immunol Res; 2015; 2015():675269. PubMed ID: 26587548 [TBL] [Abstract][Full Text] [Related]
23. Ongoing and future directions in the management of metastatic colorectal cancer: Update on clinical trials. Advani S; Kopetz S J Surg Oncol; 2019 Apr; 119(5):642-652. PubMed ID: 30852840 [TBL] [Abstract][Full Text] [Related]
24. Immunotherapy of cancer by antisense inhibition of Ii protein, an immunoregulator of antigen selection by MHC class II molecules. Xu M; Lu X; Kallinteris NL; Wang Y; Wu S; von Hofe E; Gulfo JV; Humphreys RE; Hillman GG Curr Opin Mol Ther; 2004 Apr; 6(2):160-5. PubMed ID: 15195928 [TBL] [Abstract][Full Text] [Related]
25. Antisense oligonucleotides as therapeutic agents. Alama A; Barbieri F; Cagnoli M; Schettini G Pharmacol Res; 1997 Sep; 36(3):171-8. PubMed ID: 9367660 [TBL] [Abstract][Full Text] [Related]
26. New Trends in Anti-Cancer Therapy: Combining Conventional Chemotherapeutics with Novel Immunomodulators. Wilson AL; Plebanski M; Stephens AN Curr Med Chem; 2018; 25(36):4758-4784. PubMed ID: 28875845 [TBL] [Abstract][Full Text] [Related]
27. Biological response modifiers in cancer. Reang P; Gupta M; Kohli K MedGenMed; 2006 Nov; 8(4):33. PubMed ID: 17415315 [TBL] [Abstract][Full Text] [Related]
28. Recent progress in immunotherapy for urological cancer. Obara W; Kato R; Kato Y; Kanehira M; Takata R Int J Urol; 2017 Oct; 24(10):735-742. PubMed ID: 28636222 [TBL] [Abstract][Full Text] [Related]
29. European School of Oncology Task Force Papers: gene therapy--a future in cancer management? Antisense therapy for malignant disease. O'Brien SG; Kirkland MA; Goldman JM Eur J Cancer; 1994; 30A(8):1160-4. PubMed ID: 7654449 [No Abstract] [Full Text] [Related]
31. New response criteria proposed for immunotherapies. Tuma RS J Natl Cancer Inst; 2008 Sep; 100(18):1280-1. PubMed ID: 18780859 [No Abstract] [Full Text] [Related]
32. Clinical perspectives--biologics in IBD: What's all the fuss? Steinhart H Can J Gastroenterol; 2001 Dec; 15(12):799-804. PubMed ID: 11773946 [TBL] [Abstract][Full Text] [Related]
33. Novel approaches to treating the asymptomatic hormone-refractory prostate cancer patient. Gulley J; Dahut WL Urology; 2003 Dec; 62 Suppl 1():147-54. PubMed ID: 14747053 [TBL] [Abstract][Full Text] [Related]
34. Novel agents in epithelial ovarian cancer. See HT; Kavanagh JJ Cancer Invest; 2004; 22 Suppl 2():29-44. PubMed ID: 15573743 [TBL] [Abstract][Full Text] [Related]
35. [Recent progress in biological therapies for cancer]. Saji S; Sugiyama Y; Kunieda K; Umemoto T Gan To Kagaku Ryoho; 1999 Jun; 26 Suppl 1():32-41. PubMed ID: 10410657 [TBL] [Abstract][Full Text] [Related]